JP2020533354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533354A5 JP2020533354A5 JP2020514916A JP2020514916A JP2020533354A5 JP 2020533354 A5 JP2020533354 A5 JP 2020533354A5 JP 2020514916 A JP2020514916 A JP 2020514916A JP 2020514916 A JP2020514916 A JP 2020514916A JP 2020533354 A5 JP2020533354 A5 JP 2020533354A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- composition according
- hcmv
- antigen
- full
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023198785A JP2024026160A (ja) | 2017-09-13 | 2023-11-24 | ヒトサイトメガロウイルス免疫原性組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306179 | 2017-09-13 | ||
| EP17306179.7 | 2017-09-13 | ||
| PCT/EP2018/074369 WO2019052975A1 (en) | 2017-09-13 | 2018-09-11 | IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198785A Division JP2024026160A (ja) | 2017-09-13 | 2023-11-24 | ヒトサイトメガロウイルス免疫原性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533354A JP2020533354A (ja) | 2020-11-19 |
| JP2020533354A5 true JP2020533354A5 (enExample) | 2021-09-30 |
| JP7770767B2 JP7770767B2 (ja) | 2025-11-17 |
Family
ID=60782111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514916A Active JP7770767B2 (ja) | 2017-09-13 | 2018-09-11 | ヒトサイトメガロウイルス免疫原性組成物 |
| JP2023198785A Pending JP2024026160A (ja) | 2017-09-13 | 2023-11-24 | ヒトサイトメガロウイルス免疫原性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198785A Pending JP2024026160A (ja) | 2017-09-13 | 2023-11-24 | ヒトサイトメガロウイルス免疫原性組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11524069B2 (enExample) |
| EP (1) | EP3681534A1 (enExample) |
| JP (2) | JP7770767B2 (enExample) |
| KR (2) | KR20250006307A (enExample) |
| CN (1) | CN111344009A (enExample) |
| AU (1) | AU2018331874B2 (enExample) |
| BR (1) | BR112020004747A2 (enExample) |
| CA (1) | CA3075207A1 (enExample) |
| IL (1) | IL273120B2 (enExample) |
| MX (1) | MX2020002810A (enExample) |
| SG (1) | SG11202002174SA (enExample) |
| WO (1) | WO2019052975A1 (enExample) |
| ZA (1) | ZA202001561B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020004747A2 (pt) | 2017-09-13 | 2020-09-24 | Sanofi Pasteur | composição imunogênica de citomegalovírus humano |
| JP7179872B2 (ja) * | 2018-12-10 | 2022-11-29 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| EP4237085A1 (en) * | 2020-10-28 | 2023-09-06 | Sanofi Pasteur | Liposomes containing tlr4 agonist, preparation and uses thereof |
| WO2024218752A1 (en) * | 2023-04-21 | 2024-10-24 | Instar Technologies A.S. | Pharmaceutical composition for vaccination against cytomegalovirus infections |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US6100064A (en) * | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5547834A (en) | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| KR920701453A (ko) | 1989-03-17 | 1992-08-11 | 미리엄 디. 멕코나헤이 | 유전자발현의 외부조절 |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US20020102562A1 (en) | 1995-05-24 | 2002-08-01 | Pasteur Merieux Serums Et Vaccines S.A. | Recombinant CMV neutralizing proteins |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| WO2004060396A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| CA2654563A1 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| ATE549031T1 (de) * | 2007-09-21 | 2012-03-15 | Sanofi Pasteur | Impfstoffzusammensetzung zur prävention von cmv- infektionen |
| MX2010008799A (es) | 2008-03-05 | 2010-09-07 | Sanofi Pasteur | Proceso para estabilizar una composicion de vacuna que contiene adyuvante. |
| LT2437753T (lt) | 2009-06-05 | 2016-12-12 | Infectious Disease Research Institute | Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos |
| CA2814386C (en) * | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| AR083454A1 (es) | 2010-10-15 | 2013-02-27 | Glaxosmithkline Biolog Sa | Antigeno de citomegalovirus |
| WO2012141984A1 (en) * | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| EP2729168A2 (en) * | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
| MX378747B (es) | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| AU2013293570B2 (en) * | 2012-07-27 | 2019-05-23 | City Of Hope | An MVA vaccine for delivery of a UL128 complex and preventing CMV infection |
| US20150359879A1 (en) * | 2012-10-30 | 2015-12-17 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection |
| US20170119874A1 (en) * | 2014-04-23 | 2017-05-04 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| EP3139953A1 (en) | 2014-05-08 | 2017-03-15 | Pfizer Inc. | Means and methods for treating cmv |
| EP3031822A1 (en) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| WO2017044895A2 (en) * | 2015-09-10 | 2017-03-16 | City Of Hope | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF |
| MA46316A (fr) * | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| HRP20250077T1 (hr) * | 2016-06-17 | 2025-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Nove imunogene formulacije koje sadrže ravne ili razgranate polimerne adjuvante poliakrilne kiseline |
| BR112020004747A2 (pt) | 2017-09-13 | 2020-09-24 | Sanofi Pasteur | composição imunogênica de citomegalovírus humano |
-
2018
- 2018-09-11 BR BR112020004747-3A patent/BR112020004747A2/pt not_active Application Discontinuation
- 2018-09-11 JP JP2020514916A patent/JP7770767B2/ja active Active
- 2018-09-11 KR KR1020247040905A patent/KR20250006307A/ko active Pending
- 2018-09-11 CA CA3075207A patent/CA3075207A1/en active Pending
- 2018-09-11 AU AU2018331874A patent/AU2018331874B2/en active Active
- 2018-09-11 IL IL273120A patent/IL273120B2/en unknown
- 2018-09-11 SG SG11202002174SA patent/SG11202002174SA/en unknown
- 2018-09-11 WO PCT/EP2018/074369 patent/WO2019052975A1/en not_active Ceased
- 2018-09-11 CN CN201880072392.9A patent/CN111344009A/zh active Pending
- 2018-09-11 US US16/646,894 patent/US11524069B2/en active Active
- 2018-09-11 KR KR1020207010481A patent/KR20200051778A/ko not_active Ceased
- 2018-09-11 EP EP18765127.8A patent/EP3681534A1/en active Pending
- 2018-09-11 MX MX2020002810A patent/MX2020002810A/es unknown
-
2020
- 2020-03-12 ZA ZA2020/01561A patent/ZA202001561B/en unknown
- 2020-10-15 US US17/071,817 patent/US11207403B2/en active Active
-
2022
- 2022-12-08 US US18/077,713 patent/US20230277655A1/en active Pending
-
2023
- 2023-11-24 JP JP2023198785A patent/JP2024026160A/ja active Pending
-
2025
- 2025-01-14 US US19/020,003 patent/US20250228933A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533354A5 (enExample) | ||
| Yang et al. | Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases | |
| Lin et al. | Calcium phosphate nanoparticles as a new generation vaccine adjuvant | |
| Petkar et al. | An overview of nanocarrier-based adjuvants for vaccine delivery | |
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| HRP20160816T1 (hr) | Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica | |
| O’Hagan et al. | New generation adjuvants–from empiricism to rational design | |
| Huang et al. | Research progress on emulsion vaccine adjuvants | |
| JP7053106B2 (ja) | リピドａ模倣体、調製方法、及びその使用 | |
| Alving et al. | Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines | |
| JP2014532620A5 (enExample) | ||
| Tonnis et al. | Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars | |
| Cui et al. | Vaccine adjuvants: current status, research and development, licensing, and future opportunities | |
| Bramwell et al. | Particulate delivery systems for vaccines | |
| Kaurav et al. | Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage | |
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| ES2647902T3 (es) | Método de administración de vacunas | |
| Mata et al. | Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research | |
| Sanders et al. | Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines | |
| JP2009514839A5 (enExample) | ||
| Rambe et al. | Safety and mechanism of action of licensed vaccine adjuvants | |
| Zeng et al. | In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives | |
| Nielsen et al. | ISCOMs as a vaccine delivery system | |
| Bioley et al. | Long-term persistence of immunity induced by OVA-coupled gas-filled microbubble vaccination partially protects mice against infection by OVA-expressing Listeria | |
| Jalilian et al. | Properties and prospects of adjuvants in influenza vaccination-messy precipitates or blessed opportunities? |